» Articles » PMID: 30648290

Efficacy and Safety of 308-nm Excimer Lamp in the Treatment of Scalp Psoriasis: a Retrospective Study

Overview
Date 2019 Jan 17
PMID 30648290
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Scalp psoriasis is a major therapeutic challenge due to the hindrance caused by hair. Treatment with the 308-nm excimer lamp is purported to provide many benefits over conventional phototherapy. This retrospective study evaluates the efficacy, safety, and effective dosage of 308-nm excimer light in the treatment of scalp psoriasis.

Methods: We retrospectively reviewed the medical records of patients with scalp psoriasis who received treatment with 308-nm excimer light. Clinical and epidemiological data as well as details regarding treatment were statistically analyzed to determine the treatment outcomes.

Results: Twenty patients with scalp psoriasis were included in the study. Their mean age was 47.45 ± 17.93 years. Eleven patients responded to treatment at the end of 10 sessions. The median baseline Psoriatic Scalp Severity Index (PSSI) was 12 (range, 3-32). At the end of the protocol, the median PSSI was 4.5 (range, 0-24), indicating a statistically significant reduction (P < 0.001). Common adverse effects included erythema, irritation, and desquamation.

Conclusion: The 308-nm excimer light appears to be an effective and safe modality that requires short treatment time. The modality could be considered as an alternative or adjuvant treatment for scalp psoriasis.

Citing Articles

Excimer light versus topical methotrexate 1% hydrogel in treatment of scalp psoriasis: clinical and dermoscopic study.

Moftah N, Elbakry A, Nouh N, Mohamed S Arch Dermatol Res. 2025; 317(1):282.

PMID: 39825943 DOI: 10.1007/s00403-024-03676-9.


308-nm Excimer Lamp vs. Combination of 308-nm Excimer Lamp and 10% Liquor Carbonis Detergens in Patients With Scalp Psoriasis: A Randomized, Single-Blinded, Controlled Trial.

Rattanakaemakorn P, Triyangkulsri K, Iamsumang W, Suchonwanit P Front Med (Lausanne). 2021; 8:677948.

PMID: 34211988 PMC: 8240808. DOI: 10.3389/fmed.2021.677948.


Incidence and Risk Factors of Hepatic Fibrosis in Psoriatic Patients Receiving Methotrexate with Concomitant Acitretin Therapy and Methotrexate Monotherapy.

Rattanakaemakorn P, Pinyowiwat P, Iamsumang W, Chanprapaph K, Suchonwanit P Drug Des Devel Ther. 2021; 15:2299-2307.

PMID: 34093007 PMC: 8170124. DOI: 10.2147/DDDT.S304168.


Scalp Psoriasis: A Literature Review of Effective Therapies and Updated Recommendations for Practical Management.

Mosca M, Hong J, Hadeler E, Brownstone N, Bhutani T, Liao W Dermatol Ther (Heidelb). 2021; 11(3):769-797.

PMID: 33893995 PMC: 8163911. DOI: 10.1007/s13555-021-00521-z.